By Regenerative Medicine China · Published and sources checked · Patient information and administrative due diligence, not an individual clinical opinion or legal advice.
Does “approved CAR-T for solid tumours” mean it fits my cancer?
No broad headline can establish individual eligibility. Match the exact product to the authorised indication, tumour pathology, required biomarkers, prior treatment and the proposed use. Ask the treating institution to identify the regulatory route and explain any difference between the proposal and the current product information.
Start with names that can be reconciled
Request the generic name, brand if applicable, manufacturer, product identifier or approval reference and the hospital’s proposed regimen. Research codes, generic names and commercial names may coexist; ask the institution to show how the names in your documents relate.
If the invoice describes only “immune treatment”, request a more precise description before treating it as a quote for a particular product. The name in the clinical plan, supplier documentation and consent information should be reconcilable.
A specific example: satri-cel
In its 22 June 2026 issuer announcement, CARsgen reported NMPA approval of satricabtagene autoleucel (satri-cel) for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma after failure of at least two prior treatment lines. This is a defined indication, not approval for every solid tumour. Read the issuer filing.
Use the filing as a documented example and ask the institution to provide the current approved product information. Do not infer eligibility from a news report about a patient with a broadly similar cancer description. RMC has not confirmed a satri-cel appointment, provider relationship or price for the reader.
Compare the proposed use with your records
- Exact pathological diagnosis and disease site, rather than a casual shorthand for the cancer.
- Required biomarker result, testing method and whether the institution accepts the existing laboratory report.
- Previous systemic treatment, response and reason for stopping each line.
- Current clinical condition and any further assessment the team requires.
- Whether the proposed use matches the product information or follows a different specified pathway.
These are document-matching questions, not an online eligibility score. Ask the oncologist which tests actually need repeating before purchasing additional testing.
Distinguish regulatory routes
A marketing authorisation, permission to conduct a study and a local institutional programme do not describe the same access route. Ask for the document supporting the route being proposed and the institution’s explanation of its scope. The NMPA government-services portal is an official starting point for regulatory searches; a search result alone does not resolve every clinical question.
Where a proposal is outside the labelled indication, ask the team to explain that explicitly, including its rationale, evidence, alternatives, consent and applicable institutional process. Do not describe it as ordinary labelled treatment merely because the product is approved for another use.
Connect product verification to payment
After the clinical identity is clear, ask who supplies the product, how the order is linked to the patient, what documents accompany administration and what happens if treatment cannot proceed. The hospital should explain the relevant chain of responsibility without asking the family to manage a clinical product themselves.
A verified product is only one part of the decision. The patient still needs a clinical assessment, understandable risk discussion, confirmed receiving team and a reconciled payment request. Continue with the hospital, payee and refund checklists before making commitments.
Your practical checklist
- Reconcile product names across plan, invoice and consent.
- Read the precise indication and required tests.
- Ask for the proposed regulatory or research route.
- Leave individual eligibility to the treating team.
Common questions
Does a positive biomarker guarantee CAR-T eligibility?
No. Pathology, prior treatment, current health and the full institutional criteria still need specialist review.
Can I use another patient’s quotation to book treatment?
No. It does not establish your treatment plan, eligibility, current supplier arrangement or price.
Sources and scope
Sources support the factual context described above. The checklists are RMC’s suggested questions, not official mandatory document lists. US sources are background guidance and do not establish Chinese law, local insurance cover or an individual institution’s terms. Public-source review is not certification of a hospital, payee or treatment.